Vaxart (NASDAQ:VXRT) Stock Passes Below 200 Day Moving Average - Time to Sell?

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report)'s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.53 and traded as low as $0.30. Vaxart shares last traded at $0.35, with a volume of 2,480,363 shares.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Vaxart to a "hold" rating in a research report on Thursday, May 22nd. B. Riley dropped their target price on Vaxart from $2.50 to $2.00 and set a "buy" rating on the stock in a research report on Thursday, March 27th.

Vaxart Stock Down 4.0%

The stock has a fifty day moving average of $0.46 and a two-hundred day moving average of $0.53. The stock has a market cap of $98.43 million, a price-to-earnings ratio of -1.59 and a beta of 1.14.

Vaxart (NASDAQ:VXRT - Get Free Report) last announced its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.07). Vaxart had a negative return on equity of 91.89% and a negative net margin of 122.63%. The business had revenue of $20.88 million for the quarter, compared to analyst estimates of $2.85 million. Equities research analysts anticipate that Vaxart, Inc. will post -0.39 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Steven Lo bought 100,000 shares of the stock in a transaction dated Monday, May 19th. The stock was bought at an average cost of $0.49 per share, with a total value of $49,000.00. Following the completion of the acquisition, the insider owned 100,000 shares of the company's stock, valued at $49,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Vaxart

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VXRT. Bank of America Corp DE increased its stake in shares of Vaxart by 10.8% in the fourth quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company's stock worth $122,000 after acquiring an additional 17,942 shares during the last quarter. Invesco Ltd. increased its position in Vaxart by 48.6% during the fourth quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company's stock worth $50,000 after buying an additional 24,803 shares during the last quarter. Graham Capital Management L.P. increased its position in Vaxart by 155.8% during the fourth quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company's stock worth $35,000 after buying an additional 32,482 shares during the last quarter. Sequoia Financial Advisors LLC increased its position in Vaxart by 140.9% during the fourth quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock worth $40,000 after buying an additional 35,213 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Vaxart by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company's stock worth $1,723,000 after buying an additional 57,911 shares during the last quarter. 18.05% of the stock is owned by institutional investors.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.